

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

FITC anti-mouse CD4

RRID:AB_312713

Type: Antibody

Proper Citation

BioLegend Cat# 100510, RRID:AB_312713

Antibody Information

URL: http://antibodyregistry.org/AB_312713

Proper Citation: BioLegend Cat# 100510, RRID:AB_312713

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_312713

Vendor: BioLegend

Catalog Number: 100510

Alternative Catalog Numbers: 100509

Record Creation Time: 20250819T210508+0000

Record Last Update: 20250819T214745+0000

Ratings and Alerts

- Used for immunohistochemistry by the Human Islet Research Network community. Contact(s): [Sarah Tersey](#), [Raghu Mirmira](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for FITC anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 72 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Dong P, et al. (2026) Enhanced HIF-1 α cooperation by a human ROR γ t mutant potentiates Th17 pathogenicity. Cell reports, 45(4), 117123.

Liu X, et al. (2026) Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade-Induced Immune-Related Adverse Events in Multiple Organs. Cancer research, 86(15), 3720.

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. Cell reports, 45(5), 117324.

Fransson J, et al. (2026) Spatiotemporal analysis reveals distinct inflammatory programs underlying chronic colitis. Immunity, 59(6), 1599.

Lam JY, et al. (2026) Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses. EBioMedicine, 126, 106228.

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine, 102932.

Dai L, et al. (2026) Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling. Cell reports, 45(2), 116913.

Meng X, et al. (2026) Long-term vagus nerve stimulation synergized with rapamycin elicits neuroimmune modulation to prolong skin allograft survival. iScience, 29(4), 115189.

Kang E, et al. (2026) Creatine uptake promotes dendritic cell activation and enhances antitumor immunity. iScience, 29(4), 115436.

Wang J, et al. (2026) The phosphatase DUSP2 constrains lymphoid remodeling and immunotherapy response in lung squamous carcinoma. *Molecular therapy : the journal of the American Society of Gene Therapy*, 34(7), 4279.

Zhang G, et al. (2025) Myeloid-lineage-specific membrane protein LRRC25 suppresses immunity in solid tumor and is a potential cancer immunotherapy checkpoint target. *Cell reports*, 44(5), 115631.

Tang D, et al. (2025) Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. *Cell reports. Medicine*, 6(7), 102211.

Ding X, et al. (2025) *Bacteroides fragilis* promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. *Cell host & microbe*, 33(6), 941.

Cohen JA, et al. (2025) KMT2D coordinates antiviral CD4+ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. *Cell reports*, 44(6), 115775.

Fan Q, et al. (2025) Hepatic Lamp2a deficiency promotes inflammation of murine autoimmune cholangitis via affecting bile acid metabolism. *iScience*, 28(2), 111804.

Mauvais FX, et al. (2025) Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors. *Immunity*, 58(4), 843.

Labiano S, et al. (2025) Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. *Cell reports. Medicine*, 6(7), 102204.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Amon L, et al. (2025) GM-CSF and specific type 2 cytokines induce CD103+ and CD301b+ cell states in cDC1s and cDC2s. *Cell reports*, 44(12), 116589.